buyModerate cluster of 4
Perceptive Advisors LLC bought $20M of CERE
director at Cerevel Therapeutics Holdings, Inc.. 876,808 shares at an average of $22.81, traded Oct 16, 2023, filed Oct 17, 2023.
Conviction score
58Value
$20M
876,808 shares
Holdings after
10,794,876
+9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$20.0M at market
- +3Relative to holdingsHoldings up 9%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (2 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-23-019470, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +876,808 | $22.81 | $20M | 10,794,876 | Oct 17, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $1.0M 25,000 shares | -49% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.0M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.